Several months after Exscientia merger, AI biotech outfit Recursion reworks pipeline

Evidently in the mood for some spring cleaning, Salt Lake City’s Recursion is clearing out a chunk of its pipeline as it narrows its focus on R&D in oncology and rare diseases.

The move comes roughly six months after Recursion acquired fellow AI drug discovery outfit Exscientia in a deal that closed in November.